Protease Formulation for Treatment of Toxins
AssigneesQueen's University at Kingston, Kingston Health Sciences Centre
InventorsPrameet Sheth, Shu-Mei He, Curtis Noordhof
Life of this patent
Estimating the term…
Abstract
A method for treatment of one or more toxin(s) in a subject, that includes administering to the subject a therapeutically effective amount of a serine protease that enzymatically cleaves certain toxins. Also, a method for preventing disease progression in a subject infected by Clostridioides difficile (CD), diarrhea, or infectious colitis, which includes administering to the subject a therapeutically effective amount of the protease. The protease retains its activity up to 65° C. Treatment with the protease in mice infected with CD conferred a 10-fold survival benefit compared to mice infected with CD and untreated.
Claims35
A method for treatment of one or more toxin(s) in a subject, the method comprising administering to the subject a therapeutically effective amount of a protein that comprises HTRA-NS protein (SEQ ID NO:3).
A method for preventing disease progression in a subject infected by Clostridioides difficile, diarrhea, or infectious colitis, the method comprising administering to the subject a therapeutically effective amount of a protein comprising HTRA-NS protein (SEQ ID NO:
- 3).
A method for the prophylaxis of one or more toxin(s) in a subject, the method comprising administering to the subject a therapeutically effective amount of a protein comprising HTRA-NS protein (SEQ ID NO:
- 3).
A pharmaceutical preparation comprising a therapeutically effective amount of a protein comprising HTRA-NS protein (SEQ ID NO:
- 3) and a pharmaceutically acceptable excipient.
A composition comprising a protein comprising HTRA-NS (SEQ ID NO:
- 3), and a pharmaceutically acceptable excipient.
A protein comprising HTRA-NS (SEQ ID NO:
- 3).
A method comprising administering the composition of claim 33.
Dependencies are inferred from the claim text.